Ponatinib (AP24534)

Catalog No.S1490

Molecular Weight(MW): 532.56

Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively.

Cited by 36 Publications

Nature, 2016, 534(7609):647-51

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14329

PubMed: 25970250 ( click the link to review the publication )

Cancer Cell, 2012, 22(5):656-67

PubMed: 23153538 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Exp Dermatol, 2019, 10.1111/exd.14010

PubMed: 31338879 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2019, 46(2):126-136

PubMed: 30251267 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1405-1415

PubMed: 29695637 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-17-0008

PubMed: 28500237 ( click the link to review the publication )

Gut, 2016, 10.1136/gutjnl-2015-310382

PubMed: 26953272 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Nat Commun, 2015, 6:7002

PubMed: 25926053 ( click the link to review the publication )

Leukemia, 2015, 29(5)

PubMed: 25394714 ( click the link to review the publication )

Leukemia, 2015, 29(12):2390-2

PubMed: 26108694 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120841

PubMed: 25803811 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Sci Transl Med, 2014, 6(261):261ra152

PubMed: 25378644 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Genome Biol, 2014, 15(8):428

PubMed: 25315765 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2092-103

PubMed: 24436473 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 10.1073/pnas.1321173111

PubMed: 24550512 ( click the link to review the publication )
Mol Cancer Ther, 2014, 13(10):2315-27

PubMed: 25053825 ( click the link to review the publication )

Structure, 2014, 22(12):1764-74

PubMed: 25465127 ( click the link to review the publication )

Thrombo Res, 2014, 135(1):155-60

PubMed: 25527332 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 446(1):54-60

PubMed: 24565842 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

Harvard University, 2014, Rachel Grace Liao

PubMed: ( click the link to review the publication )

Clin Cancer Res, 2013, 19(6):1422-32

PubMed: 23319824 ( click the link to review the publication )

Cancer Res, 2013, 73(16):5195-205

PubMed: 23786770 ( click the link to review the publication )

Neoplasia, 2013, 15(8):975-88

PubMed: 23908597 ( click the link to review the publication )

Curr Cancer Drug Targets, 2012, 12(5):505-21

PubMed: 22483156 ( click the link to review the publication )

Exp Hematol, 2012, 41(4):335-45.e3

PubMed: 23287417 ( click the link to review the publication )

Mol Genet Metab, 2010, 100(4):309-15

PubMed: 20554235 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcr-Abl Inhibitors

Biological Activity

Description

Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively.

Targets

Abl ^[1] (Cell-free assay)	PDGFRα ^[1] (Cell-free assay)	VEGFR2 ^[1] (Cell-free assay)	FGFR1 ^[1] (Cell-free assay)	c-Src ^[1] (Cell-free assay)	View More
0.37 nM	1.1 nM	1.5 nM	2.2 nM	5.4 nM	View More

In vitro

AP24534 potently inhibits native Abl, Abl^T315I, and other clinically important Abl kinase domain mutants with IC50 of 0.30 nM–2 nM. AP24534 doesn't inhibit Aurora kinase family members, nor does it inhibit insulin receptor or CDK2/cyclin E. AP24534 inhibits proliferation of Ba/F3 cells expressing Bcr-Abl with IC50 of 0.5 nM, as well as Ba/F3 cells expressing a range of Bcr-Abl mutants with IC50 of 0.5 nM–36 nM. The inhibition of proliferation by AP24534 is correlated with induction of apoptosis. ^[1-2] In leukemic cell lines containing activated forms of FLT3, KIT, FGFR1, and PDGFRα receptors, AP24534 potently inhibits receptor phosphorylation and cellular proliferation with IC50 of 0.3 nM to 20 nM. In MV4-11 (FLT3-ITD(+/+)) but not RS4;11 (FLT3-ITD(–/–)) AML cells, AP24534 inhibits FLT3 signaling and induced apoptosis at less than 10 nM. AP24534 inhibits viability of primary leukemic blasts from a FLT3-ITD positive AML patient with IC50 of 4 nM but not those from patients with AML expressing native FLT3. ^[3] In Ba/F3 cells engineered to express activated FGFR1-4, AP24534 potently inhibits FGFR-mediated signaling and viability with IC50 lower than 40 nM. In cell lines representing multiple tumor types (endometrial, bladder, gastric, breast, lung, and colon), and containing FGFRs dysregulated by a variety of mechanisms, AP24534 inhibits FGFR-mediated signaling with IC50 less than 40 nM and inhibits cell growth with IC50 of 7 nM–181 nM. ^[4]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwMECwNFAxODN3OTFOwG0>	MVnTRW5ITVJ?
MV-4-11	M13Tcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHKPWZ1UUN3ME2wMlAxODB7NU[g{txO	M1v1cnNCVkeHUh?=
MEG-01	M4LTe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn[zTWM2OD1yLkCwNFEzQCEQvF2=	NX7DXodxW0GQR1XS
LAMA-84	NV3yRmlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3e3eWlEPTB;MD6wNFAyPjVizszN	M2e3OXNCVkeHUh?=
CGTH-W-1	NXrMZoVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTYPGRMUUN3ME2wMlAxOTZ7IN88US=>	NVnUeGd5W0GQR1XS
KASUMI-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInQenRKSzVyPUCuNFAzOTdizszN	MV7TRW5ITVJ?
BE-13	NIrBeppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\1Z2lEPTB;MD6wNFI2QSEQvF2=	NWDqTI85W0GQR1XS
CTV-1	M{XpPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPyTWM2OD1yLkCwOVIyKM7:TR?=	NVLuRolYW0GQR1XS
NKM-1	M3rReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XIOGlEPTB;MD6wNFY2PSEQvF2=	MXTTRW5ITVJ?
MONO-MAC-6	M{fke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwMEC4N\|ch\|ryP	M2nQVXNCVkeHUh?=
A204	NFWwXWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLYTWM2OD1yLkCxNlE5KM7:TR?=	M{jSUnNCVkeHUh?=
GDM-1	M{PhZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILKUpZKSzVyPUCuNFE5OzNizszN	M2XlbHNCVkeHUh?=
AN3-CA	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XENGlEPTB;MD6wNVg4OyEQvF2=	M3LFSXNCVkeHUh?=
BL-70	M33FU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwMEKxPVkh\|ryP	M2rmVXNCVkeHUh?=
Daudi	M2O1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rlRWlEPTB;MD6wNlU{PyEQvF2=	NI\nZ\|FUSU6JRWK=
KU812	NGrybnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2GyemlEPTB;MD6wNlg1QCEQvF2=	MmSyV2FPT0WU
KG-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPsdZBlUUN3ME2wMlA{Ojl2IN88US=>	NHXnbZlUSU6JRWK=
DOHH-2	Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjqTmxGUUN3ME2wMlA1QDB\|IN88US=>	MnHwV2FPT0WU
HuO9	NX3EU4l2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\0eGlEPTB;MD6wOVQ1QCEQvF2=	M3H6UnNCVkeHUh?=
EB2	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;KTWM2OD1yLkC1OVc3KM7:TR?=	M3vNcXNCVkeHUh?=
G-402	M2fjWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTBwME[zOFEh\|ryP	NWHSfplSW0GQR1XS
SU-DHL-1	M3nWSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTnOmN3UUN3ME2wMlA3Ozd7IN88US=>	NUjIe4k4W0GQR1XS
NCI-H719	NYfmeVNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPBfJlxUUN3ME2wMlA4QDh6IN88US=>	MWfTRW5ITVJ?
MLMA	NWezSZhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjGTWM2OD1yLkC5NFYh\|ryP	MXzTRW5ITVJ?
KM12	NV2xPYQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXj0NlcyUUN3ME2wMlA6PzN5IN88US=>	NFHLWnRUSU6JRWK=
SUP-T1	MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjiTWM2OD1yLkC5PVgzKM7:TR?=	M{XXZXNCVkeHUh?=
MZ1-PC	NHzuRmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2D1Z2lEPTB;MD6xNVM{PiEQvF2=	M2HURXNCVkeHUh?=
MFE-296	NY\p[ZA{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjOUIdKSzVyPUCuNVE5OzlizszN	NUXsbpY3W0GQR1XS
ALL-PO	MkTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zj[GlEPTB;MD6xNlQ1OyEQvF2=	Mkj6V2FPT0WU
GB-1	M2SxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfFT2RKSzVyPUCuNVI2OTJizszN	NE\FVYlUSU6JRWK=
SIG-M5	M3nUbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zXWmlEPTB;MD6xN\|M4KM7:TR?=	M1P0O3NCVkeHUh?=
P30-OHK	NEP0RYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XDOmlEPTB;MD6xOVY4OiEQvF2=	NEPCPJlUSU6JRWK=
NCI-H716	M2K3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknaTWM2OD1yLkG2NlY3KM7:TR?=	NFvvVmFUSU6JRWK=
MPP-89	M3LBZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTBwMU[5N\|Mh\|ryP	M{DxRnNCVkeHUh?=
SF126	Mn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M362bGlEPTB;MD6xO\|A3OyEQvF2=	NEnmSZlUSU6JRWK=
CTB-1	NW\1elk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1:1fmlEPTB;MD6xO\|MyPiEQvF2=	M1GwS3NCVkeHUh?=
CA46	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG[wNXNKSzVyPUCuNVc1QDlizszN	MkPrV2FPT0WU
NCI-H520	MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTBwMUe3N\|Ih\|ryP	MXXTRW5ITVJ?
CAL-85-1	NG\nZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvWPG1KSzVyPUCuNVc6OjdizszN	M3WySXNCVkeHUh?=
NCI-H2342	M33RWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofsTWM2OD1yLkG4OVc4KM7:TR?=	MWHTRW5ITVJ?
697	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGn0VJZKSzVyPUCuNVg5PzFizszN	MWHTRW5ITVJ?
NY	NYnWcGQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTBwMUmyPFch\|ryP	NIXtNWVUSU6JRWK=
T98G	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTBwMUmzNVgh\|ryP	M2DsfnNCVkeHUh?=
NCI-H1703	MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwMUm2NVUh\|ryP	M{DUe3NCVkeHUh?=
NCI-H2087	NUDEUnhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXGXHc4UUN3ME2wMlIxPDN7IN88US=>	MVXTRW5ITVJ?
PF-382	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwMkC4O\|Mh\|ryP	MVrTRW5ITVJ?
HCT-116	NEXHUWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTBwMkGwOlkh\|ryP	MmexV2FPT0WU
CAKI-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTBwMkG2OlYh\|ryP	NGnPSZdUSU6JRWK=
CCF-STTG1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7Z[ZB1UUN3ME2wMlIzPDd3IN88US=>	M3fZUHNCVkeHUh?=
D-392MG	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4j4VmlEPTB;MD6yN\|E4PyEQvF2=	MoTEV2FPT0WU
RT-112	Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;6TWM2OD1yLkKzO\|k2KM7:TR?=	NXq1eVk2W0GQR1XS
MES-SA	NGPoVHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXWzVFB{UUN3ME2wMlI1OTh5IN88US=>	M1W2dHNCVkeHUh?=
LC-2-ad	NILTR3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPMVJFGUUN3ME2wMlI1OjZ3IN88US=>	NWPBU3A6W0GQR1XS
NOS-1	NGHz[HhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjyTWM2OD1yLkK0N\|Y4KM7:TR?=	NWrjfncxW0GQR1XS
NALM-6	MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwMkW1OFMh\|ryP	NGrFT\|ZUSU6JRWK=
TE-15	MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDuZ4dKSzVyPUCuNlYxQTFizszN	M4DafXNCVkeHUh?=
786-0	MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\Jb5loUUN3ME2wMlI3OjJ6IN88US=>	NVTES\|JrW0GQR1XS
IST-MES1	M3j3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnOeYxmUUN3ME2wMlI3QDJ7IN88US=>	NYDlV21YW0GQR1XS
KYSE-180	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWP3SVFMUUN3ME2wMlI3QDlzIN88US=>	MlTUV2FPT0WU
YT	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjQT\|JxUUN3ME2wMlI3QTd2IN88US=>	MWDTRW5ITVJ?
A427	M4rHSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4DyV2lEPTB;MD6yO\|I3PCEQvF2=	M1HYWXNCVkeHUh?=
KYSE-450	M37aT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVG4XlNnUUN3ME2wMlI4OzJ7IN88US=>	M{PibnNCVkeHUh?=
HuH-7	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\xTWM2OD1yLkK3O\|Y{KM7:TR?=	NV7ENYVpW0GQR1XS
CAS-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLaTWM2OD1yLkK4N\|A{KM7:TR?=	NHG3bIFUSU6JRWK=
KURAMOCHI	M4rNT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTBwMki0NVkh\|ryP	NYXkSXBzW0GQR1XS
ACHN	M3zkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI\CNYZKSzVyPUCuNlk{OjNizszN	MWfTRW5ITVJ?
HGC-27	M{HTNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGnt[Y9KSzVyPUCuNlk{PTNizszN	NFrJeIdUSU6JRWK=
A172	NUHoVW9nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTBwMkm1O\|ch\|ryP	M1rUNXNCVkeHUh?=
SNU-449	M{L4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\KbnlKSzVyPUCuNlk6PjRizszN	NVfsfZk1W0GQR1XS
SW982	Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLJTWM2OD1yLkK5PVc5KM7:TR?=	MkO5V2FPT0WU
EFO-21	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHFTWM2OD1yLkOwOFEyKM7:TR?=	MkLBV2FPT0WU
NCI-H2030	NXfjcY12T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTBwM{GxOlQh\|ryP	Mk[3V2FPT0WU
HT-144	M1[wWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWT1fIxuUUN3ME2wMlMyOjhizszN	NILRSXNUSU6JRWK=
MFE-280	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XQVmlEPTB;MD6zNVQ2OyEQvF2=	M4XYfnNCVkeHUh?=
SK-LU-1	NHTTTWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDDTWM2OD1yLkOxOFY3KM7:TR?=	M1TZ[nNCVkeHUh?=
NCI-H2052	NGrrZZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTBwM{G0PFQh\|ryP	NV74bGZCW0GQR1XS
SK-HEP-1	NVn1[Jh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\FbWlEPTB;MD6zN\|M3QCEQvF2=	NH7ERlRUSU6JRWK=
QIMR-WIL	M{DqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{W3S2lEPTB;MD6zN\|QzPCEQvF2=	MYPTRW5ITVJ?
A2780	NETr[nVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwM{SzNFQh\|ryP	NU\ZVG5CW0GQR1XS
ACN	NEiycYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwM{S4O\|Mh\|ryP	MkXCV2FPT0WU
BxPC-3	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVL2NVVTUUN3ME2wMlM1QTh7IN88US=>	NXrye5ZlW0GQR1XS
BCPAP	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4fHOGlEPTB;MD6zOlAxOSEQvF2=	NEntXHhUSU6JRWK=
HOP-62	NE\GfFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1[xdWlEPTB;MD6zOlExPiEQvF2=	M375[HNCVkeHUh?=
SW1710	NH;HNGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PqUWlEPTB;MD6zOlQ2PSEQvF2=	M17uUHNCVkeHUh?=
OPM-2	Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zqcWlEPTB;MD6zOlQ4OyEQvF2=	MV\TRW5ITVJ?
DBTRG-05MG	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjnV25TUUN3ME2wMlM5ODV2IN88US=>	M2fNSHNCVkeHUh?=
SK-MEL-24	M1HMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\2[5hrUUN3ME2wMlM6PzlzIN88US=>	MUjTRW5ITVJ?
8305C	NXvVRWRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTBwM{m3PVMh\|ryP	MmKxV2FPT0WU
OVCAR-4	Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\POFJKSzVyPUCuOFE2QDZizszN	M1XiSnNCVkeHUh?=
HLE	NV3zbYVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LGXWlEPTB;MD60NVg3KM7:TR?=	NUPO[nQ3W0GQR1XS
NCI-H747	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PHSGlEPTB;MD60NlE{PyEQvF2=	MkLSV2FPT0WU
SW780	NYXTWWt7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnpU2luUUN3ME2wMlQzOzR4IN88US=>	MWjTRW5ITVJ?
KYSE-150	MonTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknOTWM2OD1yLkSyOFE2KM7:TR?=	M2jq[HNCVkeHUh?=
H4	M1W1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrzS4lKSzVyPUCuOFI1PTFizszN	NGLQ[ldUSU6JRWK=
SW1088	M1fGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrFTWM2OD1yLkS0N\|kh\|ryP	Mn3oV2FPT0WU
SF268	MnPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHnd5BKSzVyPUCuOFQ5PiEQvF2=	NYfCUI9nW0GQR1XS
RT4	M1;XeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXxbWRuUUN3ME2wMlQ2OTFzIN88US=>	NGHReGFUSU6JRWK=
NCI-H522	MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrST41KSzVyPUCuOFUzPyEQvF2=	NEToZ2dUSU6JRWK=
LCLC-97TM1	MkLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX22b\|FQUUN3ME2wMlQ3OTl3IN88US=>	NHXs[oNUSU6JRWK=
CAL-39	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwNE[1NVkh\|ryP	MVvTRW5ITVJ?
CAL-120	M{P1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\sSVk1UUN3ME2wMlQ4PjR\|IN88US=>	MlziV2FPT0WU
ESS-1	M1G3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvuTWM2OD1yLkS3PFIyKM7:TR?=	MUHTRW5ITVJ?
KARPAS-45	NIPSVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\4TWM2OD1yLkS4PVM{KM7:TR?=	Mor5V2FPT0WU
DU-4475	NY\DSHVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljwTWM2OD1yLkS5OVEyKM7:TR?=	NEnIcnlUSU6JRWK=
VMRC-RCZ	NUTwZ\|JvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkntTWM2OD1yLkS5PVA1KM7:TR?=	MoDWV2FPT0WU
HOS	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvwVIZKSzVyPUCuOVA{PjVizszN	NU\YbopvW0GQR1XS
MOLT-16	NHLGUWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXT5fos4UUN3ME2wMlUyQDB6IN88US=>	MoThV2FPT0WU
RPMI-6666	NUfITY9XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTBwNUKxN\|Uh\|ryP	M17kW3NCVkeHUh?=
K052	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4r4dmlEPTB;MD61NlE1KM7:TR?=	MoHYV2FPT0WU
EHEB	NVrsSXNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3UdZl5UUN3ME2wMlUzOTh{IN88US=>	M4\yfHNCVkeHUh?=
MFH-ino	MnX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2L5bGlEPTB;MD61NlM2OSEQvF2=	MoTVV2FPT0WU
A4-Fuk	M3j4O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTJOGlpUUN3ME2wMlUzPTJ6IN88US=>	M2PqWnNCVkeHUh?=
SW1417	NVvrPZl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLIXGJKSzVyPUCuOVI4QDFizszN	NWDCSpplW0GQR1XS
DoTc2-4510	MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XVe2lEPTB;MD61OFk2QCEQvF2=	NH3Ge3RUSU6JRWK=
TE-12	M4LCN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\tfY9KSzVyPUCuOVU4OzVizszN	NHXMeVdUSU6JRWK=
8-MG-BA	MlPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDpTWM2OD1yLkW2NFU3KM7:TR?=	NFHyO5NUSU6JRWK=
ECC12	NXjPZ2toT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWjJR\|UxRTBwNU[1OVgh\|ryP	NH3TV2FUSU6JRWK=
CHL-1	M{TLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTBwNUe0OlMh\|ryP	Mn;kV2FPT0WU
LCLC-103H	NVzuOotrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIL3TohKSzVyPUCuOVg{PDRizszN	NIrhNldUSU6JRWK=
OS-RC-2	MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTBwNUizO\|kh\|ryP	MWnTRW5ITVJ?
RO82-W-1	NUWxTYFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\ac2lEPTB;MD61PVYyPSEQvF2=	NIjBUGlUSU6JRWK=
A3-KAW	MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TBSWlEPTB;MD62NVQ3PyEQvF2=	MVXTRW5ITVJ?
NCCIT	NF3MU5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTBwNkG3NVUh\|ryP	Mo\hV2FPT0WU
IST-SL2	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlSwTWM2OD1yLk[yOVIzKM7:TR?=	NXvXNIxFW0GQR1XS
GI-ME-N	NGewSZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PseWlEPTB;MD62N\|A3QSEQvF2=	NGTTZ3RUSU6JRWK=
ES6	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPYTWM2OD1yLk[zNlk2KM7:TR?=	NHPTdphUSU6JRWK=
BL-41	MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWeyOWFCUUN3ME2wMlY{OzV{IN88US=>	M2TxT3NCVkeHUh?=
Ca-Ski	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LEOGlEPTB;MD62OFgyKM7:TR?=	MYDTRW5ITVJ?
HOP-92	NEDv[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{L2R2lEPTB;MD62OVY4OiEQvF2=	M4L6RnNCVkeHUh?=
SK-LMS-1	NV\v[GVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEL3XFlKSzVyPUCuOlY1PyEQvF2=	NGLESVNUSU6JRWK=
EW-13	M2rZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfp[oVlUUN3ME2wMlY3Pzd7IN88US=>	MnLqV2FPT0WU
647-V	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTBwNkixOFgh\|ryP	MV\TRW5ITVJ?
JiyoyeP-2003	MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TwZWlEPTB;MD62PVc{QCEQvF2=	NU\iUmVyW0GQR1XS
WSU-NHL	MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDhfFNkUUN3ME2wMlcxQDh5IN88US=>	NILjPIpUSU6JRWK=
U-698-M	NYPuWmJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDPTpFKSzVyPUCuO\|ExPjNizszN	Ml;rV2FPT0WU
HC-1	NYXUS5gxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M325fWlEPTB;MD63NlQxPSEQvF2=	MV;TRW5ITVJ?
8505C	MkXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnmb4RKSzVyPUCuO\|I4PDFizszN	MWrTRW5ITVJ?
HUTU-80	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzwTWM2OD1yLkezN\|Q6KM7:TR?=	MYTTRW5ITVJ?
LB1047-RCC	NHz0bFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXHUXFKSzVyPUCuO\|M2OzhizszN	NWPBSW94W0GQR1XS
GAMG	NGfQU5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fPe2lEPTB;MD63N\|Y2OyEQvF2=	MV7TRW5ITVJ?
CAL-12T	M2jNZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTBwN{O4O\|ch\|ryP	NYPEVYxMW0GQR1XS
NCI-SNU-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{K3RmlEPTB;MD63O\|I4QCEQvF2=	Mm\mV2FPT0WU
HTC-C3	NUTFOXBtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M125WGlEPTB;MD63O\|Q2OSEQvF2=	NE[yN2JUSU6JRWK=
HPAF-II	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TvfmlEPTB;MD63O\|UxOSEQvF2=	MYDTRW5ITVJ?
KGN	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\0TWM2OD1yLke4NFgyKM7:TR?=	NFH4TI9USU6JRWK=
EFO-27	MmTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDYeJNKSzVyPUCuO\|g4OzNizszN	MVrTRW5ITVJ?
MEL-HO	M3f4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknpTWM2OD1yLke5OFQ6KM7:TR?=	NX:3OpFDW0GQR1XS
KYSE-270	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzkU4dKSzVyPUCuPFA2OjlizszN	Mn\wV2FPT0WU
NCI-H1755	M3XjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwOEC3NVQh\|ryP	NVj5NGhzW0GQR1XS
MFM-223	M2r1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrscoNKSzVyPUCuPFE1ODdizszN	M{\0d3NCVkeHUh?=
G-361	M3ezWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3Jb3BoUUN3ME2wMlgyQDl5IN88US=>	MULTRW5ITVJ?
ETK-1	M{X3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\4NZJpUUN3ME2wMlgzPDRzIN88US=>	MlS1V2FPT0WU
LU-99A	MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU[xVZZJUUN3ME2wMlg1PzBzIN88US=>	NXfv[m41W0GQR1XS
IST-MEL1	MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkL2TWM2OD1yLki1O\|MzKM7:TR?=	NHfYOJlUSU6JRWK=
L-540	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTBwOEW4NFEh\|ryP	MkjXV2FPT0WU
U-2-OS	NFHUdGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHSNJRKSzVyPUCuPFU5PDZizszN	M2HWc3NCVkeHUh?=
HT-1376	MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVG2eHQ5UUN3ME2wMlg3ODVzIN88US=>	M2TNN3NCVkeHUh?=
COLO-680N	MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDRTWM2OD1yLki3PVM{KM7:TR?=	MWnTRW5ITVJ?
NCI-H1581	MlzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlH1TWM2OD1yLki5Nlk4KM7:TR?=	MWLTRW5ITVJ?
HuCCT1	MnPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwOEm1OFgh\|ryP	M3uz[nNCVkeHUh?=
BB30-HNC	M2HxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPzUJNIUUN3ME2wMlkzPDZ7IN88US=>	NILreHNUSU6JRWK=
NCI-H2347	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrVO3lKSzVyPUCuPVMzQTJizszN	M1rKPHNCVkeHUh?=
G-401	NV;Nb\|JNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\5TWM2OD1yLkmzOlk2KM7:TR?=	NHXRS3NUSU6JRWK=
NCI-H358	NXnHWZBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3TdnlUUUN3ME2wMlk2ODF2IN88US=>	NX3x[2hjW0GQR1XS
HCC1395	M3ezSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;yVZN5UUN3ME2wMlk2PDZzIN88US=>	NHXIcm9USU6JRWK=
J82	NEPr[4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfhTWM2OD1yLkm1OVQ{KM7:TR?=	NVy3O4lzW0GQR1XS
KE-37	MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfT[GFKSzVyPUCuPVY{QDdizszN	NUfsRVQ1W0GQR1XS
NOMO-1	NEe1bVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTBwOU[1OlQh\|ryP	M3nVZ3NCVkeHUh?=
ML-2	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MniyTWM2OD1yLkm5O\|Uh\|ryP	M4nMT3NCVkeHUh?=
SW872	Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTBwOUm3O\|Uh\|ryP	M4\kSnNCVkeHUh?=
KYSE-520	NX\IVWxKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTFwMEC0PVQh\|ryP	NIfOSZlUSU6JRWK=
HL-60	M2rDOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFfWSJBKSzVyPUGuNFA6PyEQvF2=	MXTTRW5ITVJ?
HDLM-2	MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTFwMEGyOVIh\|ryP	MYLTRW5ITVJ?
MIA-PaCa-2	NV3ndolpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LIc2lEPTB;MT6wNVM4PSEQvF2=	NX3vVFJXW0GQR1XS
TCCSUP	NXLmbo9kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrM[pdKSzVyPUGuNFE4OzJizszN	MknrV2FPT0WU
SH-4	M{TwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml7LTWM2OD1zLkCyNlQ1KM7:TR?=	M3uwfnNCVkeHUh?=
MG-63	NW\TSHJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rTd2lEPTB;MT6wNlYyPiEQvF2=	NHzZNlFUSU6JRWK=
NB6	NUT2dmdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXtUlBlUUN3ME2xMlA{OTB7IN88US=>	M3LsVnNCVkeHUh?=
CAL-54	M4CxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlu1TWM2OD1zLkCzPVU6KM7:TR?=	NVHTXXpQW0GQR1XS
DU-145	NFrxVppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTFwMEiwO\|Mh\|ryP	MUfTRW5ITVJ?
HCE-4	NUf5clJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPaTWM2OD1zLkC5Nlg3KM7:TR?=	M3vqeHNCVkeHUh?=
U-266	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jsZmlEPTB;MT6wPVY{OyEQvF2=	MV\TRW5ITVJ?
HT-1197	NILtXHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTFwMUG0N\|gh\|ryP	NWHrPFhqW0GQR1XS
EW-1	M4nQfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnWwTWM2OD1zLkG0NVI5KM7:TR?=	M17jeXNCVkeHUh?=
MHH-NB-11	M3q5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTFwMUWzOlgh\|ryP	MoPXV2FPT0WU
NCI-H2405	NYHUNlUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlz6TWM2OD1zLkG2NVYh\|ryP	MVXTRW5ITVJ?
COLO-668	NVrEc2lFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jXfGlEPTB;MT6xOlQ6KM7:TR?=	NGLnWplUSU6JRWK=
IMR-5	NV;3d\|JsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2naVWlEPTB;MT6xOlk{PiEQvF2=	MoK1V2FPT0WU
ARH-77	NYHZdGlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rzZmlEPTB;MT6yNlkzPCEQvF2=	MV7TRW5ITVJ?
BHT-101	NICyPHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nzSGlEPTB;MT6yN\|Q6KM7:TR?=	NYfF[Yd[W0GQR1XS
SCC-25	M{TaSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPITWM2OD1zLkKzOVM3KM7:TR?=	MWrTRW5ITVJ?
NTERA-S-cl-D1	NEf1[HhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTFwMkSzOFYh\|ryP	MVHTRW5ITVJ?
MKN28	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1KzSGlEPTB;MT6yOVY{PiEQvF2=	Mn;lV2FPT0WU
KS-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLsclMxUUN3ME2xMlI5OjZ7IN88US=>	NFi3UpRUSU6JRWK=
NCI-H1734	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkC3TWM2OD1zLkK4PVE{KM7:TR?=	MWDTRW5ITVJ?
ES7	NV2wRpJiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDYV4k4UUN3ME2xMlI6PTR{IN88US=>	M1rFfXNCVkeHUh?=
NCI-H838	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTFwM{C2NVUh\|ryP	MlHoV2FPT0WU
HEC-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTFwM{O3OVUh\|ryP	M1XjTXNCVkeHUh?=
ME-180	M1fER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG[5eWpKSzVyPUGuN\|c6QTNizszN	Mn;sV2FPT0WU
MMAC-SF	NVe3V2h1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\5WWlEPTB;MT6zPVU6PSEQvF2=	NITLempUSU6JRWK=
IA-LM	MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGroSmVKSzVyPUGuOFA6OTRizszN	MnHMV2FPT0WU
MN-60	NW\aWFNGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHvSXFUUUN3ME2xMlQ{OTF2IN88US=>	MUPTRW5ITVJ?
SIMA	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTFwNEi2PFch\|ryP	MnXDV2FPT0WU
NCI-H1770	MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HlUWlEPTB;MT61NlA2PCEQvF2=	MlzXV2FPT0WU
ONS-76	M1i2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTvbmxKSzVyPUGuOVI{OTFizszN	NI\u[YNUSU6JRWK=
LB771-HNC	MnTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTXfGpKSzVyPUGuOVM6ODZizszN	NV25cmxrW0GQR1XS
SW48	NWLIN4c6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;TSZhGUUN3ME2xMlU1OjR\|IN88US=>	NVzHXVRlW0GQR1XS
KYSE-140	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTFwNUW3OFEh\|ryP	MXHTRW5ITVJ?
SW626	NI\xS49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonHTWM2OD1zLkW4NVYh\|ryP	Mo\FV2FPT0WU
MC-CAR	NInSSIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEf1TlRKSzVyPUGuOVg3PjNizszN	M1G5THNCVkeHUh?=
D-336MG	NGDCbVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17XWWlEPTB;MT62Nlk1KM7:TR?=	NH\TUG5USU6JRWK=
SK-MEL-3	NUjI[VV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XkUmlEPTB;MT62N\|kxOiEQvF2=	NYrNNnQ{W0GQR1XS
MHH-PREB-1	MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfJeWpmUUN3ME2xMlY1PDd\|IN88US=>	NIL4SVBUSU6JRWK=
Calu-1	NUfTfWxJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvoTWM2OD1zLk[1N\|g3KM7:TR?=	MnW5V2FPT0WU
HCC1806	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTFwNk[2NVEh\|ryP	NUPmTlBYW0GQR1XS
A101D	MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1u4fmlEPTB;MT62Olc5OSEQvF2=	NYHqOZpNW0GQR1XS
A704	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTFwNkizNVEh\|ryP	MXfTRW5ITVJ?
LB831-BLC	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTQSIxKSzVyPUGuOlk5PTRizszN	MkXZV2FPT0WU
RL95-2	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjacIFKSzVyPUGuO\|E1PjNizszN	MlH5V2FPT0WU
RPMI-2650	NIXXT2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vibGlEPTB;MT63NlcyQSEQvF2=	M{\VN3NCVkeHUh?=
NH-12	M4n3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1T3SGlEPTB;MT63N\|QzPyEQvF2=	NFvSfVFUSU6JRWK=
AGS	Mn;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWq1RWYzUUN3ME2xMlc3OzV6IN88US=>	MkjJV2FPT0WU
NEC8	NGW4fVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDFb4pKSzVyPUGuO\|g6QTVizszN	MXHTRW5ITVJ?
NCI-H2009	NGTiRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4WwVGlEPTB;MT63PVczOSEQvF2=	NV3aR5JFW0GQR1XS
A498	NYTVTmJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTFwOEGyPFIh\|ryP	MlXIV2FPT0WU
NCI-H810	NU\uO\|ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUP5V445UUN3ME2xMlgyPjB4IN88US=>	MnjHV2FPT0WU
SK-NEP-1	M{DKR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTFwOEO3Olch\|ryP	NYfPW3E3W0GQR1XS
D-542MG	NWDZcJZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjQTXA{UUN3ME2xMlg2QDVzIN88US=>	MU\TRW5ITVJ?
KNS-42	NYT6emVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnRTWM2OD1zLki2NlY3KM7:TR?=	M3fTdXNCVkeHUh?=
NCI-H2452	NWL3[ldIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTFwOEmwO\|Qh\|ryP	M1HhTXNCVkeHUh?=
SK-MEL-2	Mm\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYj3Z3B1UUN3ME2xMlkxOjdzIN88US=>	MXzTRW5ITVJ?
OVCAR-5	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTFwOUC2O\|Uh\|ryP	MUDTRW5ITVJ?
SNG-M	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\RXnJKSzVyPUGuPVU5PThizszN	MX3TRW5ITVJ?
A673	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlS1TWM2OD1zLkm3OVE3KM7:TR?=	NYPwell{W0GQR1XS
L-428	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYq5XWhJUUN3ME2xMlk6OTd7IN88US=>	NHjnNoRUSU6JRWK=
KM-H2	M4fRemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPCOYpKSzVyPUKuNFExQSEQvF2=	MYPTRW5ITVJ?
MC-IXC	MlzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;idVFKSzVyPUKuNFIzPzNizszN	MlXUV2FPT0WU
COLO-678	MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn[xTWM2OD1{LkC0NlA4KM7:TR?=	Mln0V2FPT0WU
MEL-JUSO	NH\sSldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTJwMEe4OVEh\|ryP	MkH2V2FPT0WU
HCC38	NETBOnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTmTWM2OD1{LkC4OFM{KM7:TR?=	NH\CXpZUSU6JRWK=
UACC-62	NVLlcodqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3nTWM2OD1{LkC4PFU2KM7:TR?=	MljiV2FPT0WU
OAW-42	NXHITZZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU[2XXd1UUN3ME2yMlA6PzFzIN88US=>	Mm\aV2FPT0WU
LB996-RCC	NIDw[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3r2d2lEPTB;Mj6xN\|gyPyEQvF2=	NVq3fVVwW0GQR1XS
COR-L105	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjDTWM2OD1{LkG2N\|c{KM7:TR?=	MWXTRW5ITVJ?
RCC10RGB	NWPZSoQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnxTWM2OD1{LkG4OVc3KM7:TR?=	MnGzV2FPT0WU
A431	NVTYOopWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPETpBGUUN3ME2yMlE6ODF7IN88US=>	NGHFUoFUSU6JRWK=
NCI-H292	NIryNYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjY[ZJ4UUN3ME2yMlI{QTVzIN88US=>	NX;nXJJRW0GQR1XS
SK-UT-1	NInIT41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\UTWM2OD1{LkOzNVg1KM7:TR?=	M13XNnNCVkeHUh?=
PANC-08-13	NEHnRXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWP5UW0yUUN3ME2yMlM{OjN3IN88US=>	MVLTRW5ITVJ?
ST486	M2\ke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmW5TWM2OD1{LkSxNFQ5KM7:TR?=	MkHIV2FPT0WU
SJSA-1	Mn\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7XVXJ[UUN3ME2yMlQyOjdzIN88US=>	M3vCW3NCVkeHUh?=
RKO	NUHZXm5[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoP4TWM2OD1{LkSyNFI6KM7:TR?=	NUDTPXBiW0GQR1XS
NCI-H1793	Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHS3bm5KSzVyPUKuOFQxOjlizszN	MoD4V2FPT0WU
639-V	NYX5T2Q2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2PzeWlEPTB;Mj60OVM5OiEQvF2=	M{HWenNCVkeHUh?=
ES3	M2P0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLsVoZLUUN3ME2yMlQ6PzN5IN88US=>	NY\FTXQ6W0GQR1XS
NCI-H1792	NYWwZZdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LMdmlEPTB;Mj61OlgzPiEQvF2=	MUPTRW5ITVJ?
NCI-H1651	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHh[4sxUUN3ME2yMlU5OjFizszN	NGnBdpRUSU6JRWK=
SN12C	NYrHfVhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTJwNUi0PFch\|ryP	M2LrUXNCVkeHUh?=
COLO-679	NGTEeGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\pW3FKSzVyPUKuOVg3ODVizszN	MlPvV2FPT0WU
U-118-MG	NX6xZ2dPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLBTWM2OD1{LkW4PFczKM7:TR?=	NX2zO\|I1W0GQR1XS
Ramos-2G6-4C10	NIS3WGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXrRXpKSzVyPUKuOlQ5ODdizszN	NELkblZUSU6JRWK=
HCT-15	MkjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTJwNki3PVIh\|ryP	NVHITG1OW0GQR1XS
MDA-MB-157	NWfTZZpqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkP4TWM2OD1{LkewO\|Q4KM7:TR?=	NV\Jdpg1W0GQR1XS
K5	NGWwd5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnlRpVKSzVyPUKuO\|E5PDVizszN	MXjTRW5ITVJ?
MKN45	NXLtXpozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTJwN{OzOlYh\|ryP	NX\Ne\|B4W0GQR1XS
DMS-273	NH\qPIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mkn3TWM2OD1{Lke1OlMzKM7:TR?=	M3XOO3NCVkeHUh?=
C8166	NES3RpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoH1TWM2OD1{Lke4OVE{KM7:TR?=	M1TXdHNCVkeHUh?=
Calu-3	MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXn6UG1VUUN3ME2yMlc5QTZ7IN88US=>	MlzxV2FPT0WU
SNB75	NFK5WY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIT0coxKSzVyPUKuPFg2OzVizszN	MUHTRW5ITVJ?
BFTC-905	M372Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTJwOUCxPVEh\|ryP	M4LIWXNCVkeHUh?=
C-4-II	NXS4[nZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnpUoZuUUN3ME2yMlkyOzV\|IN88US=>	NHTF[nVUSU6JRWK=
MS-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTJwOU[3Olkh\|ryP	Ml7HV2FPT0WU
A375	NETMVGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnzUIVKSzVyPUOuNFgyQDRizszN	M3;YfXNCVkeHUh?=
KYSE-70	NVO4[HhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jKcWlEPTB;Mz6wPFg5OiEQvF2=	NEjo[nZUSU6JRWK=
KYSE-510	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3rifmlEPTB;Mz6xNFk6PSEQvF2=	NYnafZpFW0GQR1XS
LN-405	M4jLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnKeGZKSzVyPUOuNVM2OThizszN	MX3TRW5ITVJ?
BOKU	NH\UcY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2Sz[GlEPTB;Mz6xOFI2PiEQvF2=	NH;qTIRUSU6JRWK=
TE-10	M2LWS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTNwMUezOlIh\|ryP	M1vzTnNCVkeHUh?=
MKN1	NYnaOHo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzPbHpKSzVyPUOuNVg1QDNizszN	Mn;wV2FPT0WU
M059J	M1zMW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvxTWM2OD1\|LkKwNVc{KM7:TR?=	NH\k[FJUSU6JRWK=
GOTO	M4TjRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\KTWM2OD1\|LkKyNFM6KM7:TR?=	MYPTRW5ITVJ?
DK-MG	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDXb3R6UUN3ME2zMlI2QTd4IN88US=>	NGG5V4xUSU6JRWK=
NCI-H727	M{f0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTNwMk[1PEDPxE1?	NX;KdINqW0GQR1XS
NB12	Mn\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzQWYM{UUN3ME2zMlM{OjJ2IN88US=>	NV\UNHFnW0GQR1XS
DOK	MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2CyTWlEPTB;Mz6zOlE5PiEQvF2=	MYrTRW5ITVJ?
KYSE-410	NXvp[Y9HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnabotPUUN3ME2zMlM3Ojh5IN88US=>	M1vUUnNCVkeHUh?=
AM-38	NYThNpR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rJNWlEPTB;Mz6zPFA2OSEQvF2=	NGTNZZdUSU6JRWK=
GR-ST	NV2wPIxDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV3JR\|UxRTNwNEW3N\|Ih\|ryP	Mkn1V2FPT0WU
D-247MG	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHEcG84UUN3ME2zMlQ5OjZ\|IN88US=>	Ml:yV2FPT0WU
TE-8	NIDoW\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrlTo9KSzVyPUOuOFk{OzNizszN	NHP4R\|lUSU6JRWK=
LS-411N	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnZTWM2OD1\|LkS5OlkzKM7:TR?=	NGDPcnlUSU6JRWK=
SK-MES-1	NX7YUGs3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHZTWM2OD1\|LkW2OFM{KM7:TR?=	NUnkcIZlW0GQR1XS
SF295	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIK5ZWdKSzVyPUOuOlE2PTJizszN	NIPmTlFUSU6JRWK=
SK-MEL-30	Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXJfllKSzVyPUOuOlU6OjFizszN	MlO5V2FPT0WU
LB2241-RCC	M1fye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTNwNk[yOkDPxE1?	M1f5ZXNCVkeHUh?=
PC-14	NVfIRWRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fuemlEPTB;Mz62OlQ{PyEQvF2=	NGLINlBUSU6JRWK=
EW-7	M{LkUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37wVWlEPTB;Mz62O\|Y6OyEQvF2=	NGDPNYhUSU6JRWK=
NMC-G1	M4j4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TMOmlEPTB;Mz63NVg{PyEQvF2=	MX7TRW5ITVJ?
TE-441-T	NUXFVWI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlKwTWM2OD1\|LkezNFI5KM7:TR?=	NHjxdYtUSU6JRWK=
NCI-H1618	M1zrOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTNwOEG4O\|Uh\|ryP	MVjTRW5ITVJ?
PANC-03-27	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVi2fWJtUUN3ME2zMlgyQTF4IN88US=>	NE\pXHhUSU6JRWK=
NCI-H2228	NYHU[2NpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF[3XItKSzVyPUOuPFMyOjZizszN	NVnOSVV{W0GQR1XS
CAPAN-1	M3:zZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTNwOEewNFkh\|ryP	NU[yW5ZpW0GQR1XS
KLE	MoX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDI[I1OUUN3ME2zMlkxPjdizszN	M3TufXNCVkeHUh?=
Becker	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljtTWM2OD1\|LkmyPFQ6KM7:TR?=	NGDXUJBUSU6JRWK=
SK-PN-DW	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37NSGlEPTB;ND6wO\|k4PCEQvF2=	M2rsWnNCVkeHUh?=
Hs-578-T	NG\UdpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfndnR3UUN3ME20MlA5OzB4IN88US=>	MmLDV2FPT0WU
RS4-11	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXtZ3Z1UUN3ME20MlEyOjV3IN88US=>	NFLMd\|VUSU6JRWK=
D-502MG	NF[2bo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TDZWlEPTB;ND6xOlk6PyEQvF2=	M{jqRnNCVkeHUh?=
GI-1	NYPHUIpxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIiwNoNKSzVyPUSuNlgzQTlizszN	M2fNVXNCVkeHUh?=
NCI-H209	MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\GTW5pUUN3ME20MlM{PzhizszN	NEWzSnpUSU6JRWK=
SK-OV-3	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnEc3JKSzVyPUSuOFgyPDlizszN	M{TRdXNCVkeHUh?=
LOUCY	NV\4NZZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTRwNEi0N\|Ih\|ryP	Ml;vV2FPT0WU
NCI-H69	NXTKcYVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDKTWM2OD12LkWxO\|k{KM7:TR?=	NFXDPGpUSU6JRWK=
SCC-9	NHTPdlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFj4c4hKSzVyPUSuOVMyPzJizszN	NH\hbGlUSU6JRWK=
NCI-H526	MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{[zO2lEPTB;ND61PVI6OyEQvF2=	MlHVV2FPT0WU
NCI-H2170	NEnkW\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTRwNk[3O\|Eh\|ryP	MVXTRW5ITVJ?
SR	NVP2cYtqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HrOmlEPTB;ND63NFA1QCEQvF2=	M1vtW3NCVkeHUh?=
CMK	M1TBdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1e0RmlEPTB;ND63NlExOSEQvF2=	NGfLeYtUSU6JRWK=
COLO-829	Mn7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDwSVJKSzVyPUSuO\|cxPDNizszN	MoXNV2FPT0WU
HuO-3N1	NFXWVJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XLWWlEPTB;ND64N\|I5OSEQvF2=	M2m1PHNCVkeHUh?=
5637	NWW3cY02T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTPXHp4UUN3ME20MlkxPDh5IN88US=>	M4TqS3NCVkeHUh?=
A253	NV74TY1IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TIe2lEPTB;ND65O\|cxQCEQvF2=	NFniS\|VUSU6JRWK=
NB10	M{XpSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfH[25KSzVyPUWuNFc1QTdizszN	M1[yTXNCVkeHUh?=
SF539	M33aPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTVwMEm5OVkh\|ryP	M2exNHNCVkeHUh?=
HAL-01	NHvpeWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTl[IpyUUN3ME21MlE1PjR3IN88US=>	MX\TRW5ITVJ?
MHH-ES-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUXJR\|UxRTVwMU[5NlUh\|ryP	MYjTRW5ITVJ?
DEL	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfhVYlLUUN3ME21MlI4PTh{IN88US=>	MnuxV2FPT0WU
NCI-H1299	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTGOVJKSzVyPUWuN\|UxODdizszN	NV;Lb4RSW0GQR1XS
ChaGo-K-1	NFv2NFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HacmlEPTB;NT6zOVExPyEQvF2=	M171[XNCVkeHUh?=
HMV-II	NULST2toT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnUTWM2OD13LkO5OFMh\|ryP	NWrWTHZ[W0GQR1XS
NB69	NFvKbYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHUfWx6UUN3ME21MlM6PjNzIN88US=>	M3;RfnNCVkeHUh?=
NCI-H1882	MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3r0bWlEPTB;NT60N\|M3PCEQvF2=	MkjRV2FPT0WU
SNU-475	NF;RfWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7z[YdKSzVyPUWuOFcyPzFizszN	NFrVZnZUSU6JRWK=
RXF393	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXBVZhKSzVyPUWuOFg1QTRizszN	M3LF[3NCVkeHUh?=
CAL-51	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnmR\|BKSzVyPUWuOlI5PTNizszN	Mn7kV2FPT0WU
SW1573	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPnTWM2OD13Lk[zOVM1KM7:TR?=	MWPTRW5ITVJ?
GCT	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\5OmlEPTB;NT63OVkzQSEQvF2=	MlfKV2FPT0WU
COR-L88	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVuxSpVDUUN3ME21Mlc3QDR4IN88US=>	MoTlV2FPT0WU
MDA-MB-134-VI	Ml;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLTbI1KSzVyPUWuPFc2OzZizszN	M{TLO3NCVkeHUh?=
NB5	NG[0d2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NI\vTmdKSzVyPUWuPVI1PCEQvF2=	MYjTRW5ITVJ?
GMS-10	NHTV[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDtVXAyUUN3ME21Mlk3QDZzIN88US=>	MkOzV2FPT0WU
CHP-212	NEDjfm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTZwNEiyOlch\|ryP	M3fIeHNCVkeHUh?=
TE-11	NIq1SFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXzZpJKSzVyPU[uOVUyQDJizszN	MXrTRW5ITVJ?
SW962	NVLscGJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXZZoNKSzVyPU[uOlU4PzRizszN	MVfTRW5ITVJ?
MZ2-MEL	M2XJbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTofGtKSzVyPU[uPFIxOTFizszN	M2LZd3NCVkeHUh?=
C-33-A	MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfvb3d{UUN3ME22MlkyPjh6IN88US=>	NFzuVYhUSU6JRWK=
IGR-1	Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHJemlKSzVyPU[uPVc5OjZizszN	MY\TRW5ITVJ?
MOLT-4	M{L0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTdwMUW0NFYh\|ryP	NHqyNJJUSU6JRWK=
NCI-H1650	NX3kcVFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHqb2JWUUN3ME23MlI4ODR4IN88US=>	MWnTRW5ITVJ?
AsPC-1	NHPHT5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHKTI5XUUN3ME23MlI5PjB3IN88US=>	M3Xse3NCVkeHUh?=
SNU-C2B	M1TheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnvem8xUUN3ME23MlI6PTdzIN88US=>	MonxV2FPT0WU
MKN7	M1jvR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTdwM{eyN\|Uh\|ryP	NIj6OoxUSU6JRWK=
SW620	NX;ROFV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTdwM{iyNFUh\|ryP	MWPTRW5ITVJ?
SK-MEL-28	MmSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TNUmlEPTB;Nz60NFc6QCEQvF2=	NXPVPJNtW0GQR1XS
TE-6	NWTsVYdUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Moq3TWM2OD15LkS0PVA5KM7:TR?=	Mof0V2FPT0WU
D-263MG	MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7MTWM2OD15LkS1O\|YzKM7:TR?=	M13kd3NCVkeHUh?=
NCI-H1355	MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDsd2o2UUN3ME23Mlc4ODJ7IN88US=>	NU\WdXA3W0GQR1XS
DSH1	NVPnN5V7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoT1TWM2OD15Lke5O\|YzKM7:TR?=	NVTmSHlVW0GQR1XS
NCI-H460	M4fKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHz6TWNKSzVyPUiuNFA3QTRizszN	M4T0NnNCVkeHUh?=
NCI-H1563	MofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\aTWM2OD16LkC3OVA5KM7:TR?=	MWXTRW5ITVJ?
SW948	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnK0TWM2OD16LkGwO\|Q1KM7:TR?=	M2\Ke3NCVkeHUh?=
LK-2	NFrVc5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjRPI1KSzVyPUiuNVI5OzNizszN	NYn0Omt2W0GQR1XS
HT-1080	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVW3S4xWUUN3ME24MlE{OTd3IN88US=>	NYnaW\|d4W0GQR1XS
NCI-H441	Ml3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjIT3NYUUN3ME24MlE6OyEQvF2=	NHrFOXZUSU6JRWK=
HSC-4	NEjkWmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV3JXGFYUUN3ME24MlI5PzJizszN	NHfiUYJUSU6JRWK=
LXF-289	MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRThwM{W5OFMh\|ryP	Mn3HV2FPT0WU
MRK-nu-1	M1LaOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLRe\|BiUUN3ME24MlM3OzB2IN88US=>	MUnTRW5ITVJ?
no-11	M2TxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH[4c3pKSzVyPUiuOFcyOzNizszN	MoXNV2FPT0WU
SNU-387	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3S5fGlEPTB;OD62N\|I1PiEQvF2=	NI\qRohUSU6JRWK=
Detroit562	NGfTRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\DW29KSzVyPUiuO\|U1PTVizszN	MkXYV2FPT0WU
SW954	NVrhboZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfad3NKSzVyPUiuO\|Y5OzJizszN	MnXMV2FPT0WU
P12-ICHIKAWA	M2H4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NITke\|BKSzVyPUiuO\|g6PCEQvF2=	M{jRWXNCVkeHUh?=
TE-9	M3HOfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRThwOEGwOlIh\|ryP	NXPBTXNzW0GQR1XS
NB13	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfSTHhKSzVyPUiuPFM4QTZizszN	MX\TRW5ITVJ?
BPH-1	M{m4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfofHJqUUN3ME24Mlg2ODhzIN88US=>	MV3TRW5ITVJ?
KMOE-2	M4P6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\XWGlEPTB;OD64O\|g6OiEQvF2=	M4PPTnNCVkeHUh?=
RPMI-8402	M33TTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUm5fHFHUUN3ME24Mlg6QTJ4IN88US=>	MYXTRW5ITVJ?
OVCAR-3	M4DvVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEGzcJVKSzVyPUiuPVc4OzJizszN	NXzLdnJ5W0GQR1XS
NCI-H2196	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV:1XHV4UUN3ME24Mlk5PjB4IN88US=>	NFHlOppUSU6JRWK=
MZ7-mel	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrWR2RKSzVyPUmuNFM1PiEQvF2=	MnnzV2FPT0WU
GP5d	M4fsV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELv[IFKSzVyPUmuNFY{OTNizszN	NIjnUWhUSU6JRWK=
NCI-N87	NUjhSGpHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGXs[YRKSzVyPUmuOFQ4OzFizszN	M3j0WXNCVkeHUh?=
EW-16	M3zWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nwcmlEPTB;OT60OFg1QCEQvF2=	MnjTV2FPT0WU
Calu-6	M2r4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTlwNEm3NFMh\|ryP	NHfxd21USU6JRWK=
LC4-1	NHvxSotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MknpTWM2OD17Lk[yOVch\|ryP	M{XicXNCVkeHUh?=
CCRF-CEM	NGL2UVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTlwNki3OlYh\|ryP	NILUUGVUSU6JRWK=
BC-1	MmX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;DTWM2OD17Lke4PVkh\|ryP	NGXDR4pUSU6JRWK=
NCI-SNU-16	NGPDVpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfFbZczUUN3ME25Mlc6PDl3IN88US=>	NXLESoVQW0GQR1XS
NCI-H28	M2r6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mne3TWM2OD17Lki0PVM{KM7:TR?=	M17qVnNCVkeHUh?=
SBC-1	M375emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjUb2ZKSzVyPUGwMlA4OiEQvF2=	NGrUTHdUSU6JRWK=
TUR	NXSwUlA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jRO2lEPTB;MUCuNVY2PyEQvF2=	NVPDcoI5W0GQR1XS
MDA-MB-231	M37MWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPyXodOUUN3ME2xNE4zOTF2IN88US=>	MXzTRW5ITVJ?
C3A	MmnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nvd2lEPTB;MUCuN\|E4QSEQvF2=	M1rueHNCVkeHUh?=
SW1990	NIfQW5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoK5TWM2OD1zMD6zNlgh\|ryP	NI\ZWJFUSU6JRWK=
NCI-H1993	MmnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLPS5VKSzVyPUGwMlU3QTNizszN	NXm2d2E1W0GQR1XS
SK-CO-1	NIjlTWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLPN49KSzVyPUGwMlc4PyEQvF2=	MXfTRW5ITVJ?
OAW-28	M1;2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGj3NYhKSzVyPUGwMlk5QDhizszN	MWDTRW5ITVJ?
HN	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPXZZVKSzVyPUGxMlEyOzFizszN	MYPTRW5ITVJ?
NCI-H1304	NXm3XGk{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTFzLkG1O\|Yh\|ryP	MofHV2FPT0WU
Daoy	NInURZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljjTWM2OD1zMT60N\|M3KM7:TR?=	Mn3nV2FPT0WU
VA-ES-BJ	M3zhTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MluyTWM2OD1zMT63NVk2KM7:TR?=	MYfTRW5ITVJ?
MCF7	MmrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTFzLkixNlYh\|ryP	NF:4Wm5USU6JRWK=
VM-CUB-1	M2rLXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4frNmlEPTB;MUGuPVA6OSEQvF2=	M2fKVnNCVkeHUh?=
IPC-298	M{DwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\ud2lEPTB;MUGuPVM5OyEQvF2=	NVLiSYtGW0GQR1XS
NCI-H2126	NYXRNlNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLobmpKSzVyPUGyMlAzOThizszN	NHnsbplUSU6JRWK=
OVCAR-8	M4fscGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1[zdGlEPTB;MUKuNVE1OSEQvF2=	MX;TRW5ITVJ?
SJRH30	NIfaTnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjyTWM2OD1zMj6yNlk6KM7:TR?=	MnjWV2FPT0WU
DMS-53	M1TmdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYry[ZFRUUN3ME2xNk4zPjR7IN88US=>	MVvTRW5ITVJ?
NCI-H322M	NHmyRZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonQTWM2OD1zMj6zN\|U4KM7:TR?=	NELlcHlUSU6JRWK=
RVH-421	M2D1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGLrbI5KSzVyPUGyMlQ6ODRizszN	MkL3V2FPT0WU
Raji	MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnP4TWM2OD1zMj62NVQh\|ryP	MV7TRW5ITVJ?
MDA-MB-415	NHqyTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFT3U5BKSzVyPUGyMlY1PDRizszN	NWHTWHNUW0GQR1XS
EFE-184	M4Lr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTF{LkexNFYh\|ryP	NIfDRW1USU6JRWK=
BFTC-909	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYr6PJdJUUN3ME2xNk46OjR5IN88US=>	NEi3cVlUSU6JRWK=
BHY	MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXK0W4FpUUN3ME2xN{4{OzlizszN	NV7hbFNqW0GQR1XS
YKG-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvwTWM2OD1zMz6zO\|Q6KM7:TR?=	NVTo[YF4W0GQR1XS
EW-3	Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorLTWM2OD1zMz63NVY{KM7:TR?=	NFrGcllUSU6JRWK=
HCC1143	NVnGe\|J3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TXRmlEPTB;MUOuO\|Q{PyEQvF2=	M{jCZnNCVkeHUh?=
REH	NGX2XZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTF\|Lki5PFIh\|ryP	NGfZdYpUSU6JRWK=
CESS	NUL6UIkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfJTWM2OD1zMz65OFg6KM7:TR?=	NInPOodUSU6JRWK=
EFM-19	NFy5bWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fNTGlEPTB;MUSuNVEyOiEQvF2=	MnT2V2FPT0WU
U031	M4fCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVrwW2lSUUN3ME2xOE41ODh3IN88US=>	NIfqS4hUSU6JRWK=
ES1	M1jtRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH32UmxKSzVyPUG0MlQ5PTFizszN	NULSRYtDW0GQR1XS
HSC-3	MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTF2Lk[yNVUh\|ryP	M4jheHNCVkeHUh?=
LOXIMVI	Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\UTWM2OD1zND63NFY5KM7:TR?=	NWPNcpdJW0GQR1XS
A388	NEC5XlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTF2Lke1OVYh\|ryP	M4jiXXNCVkeHUh?=
KP-N-YS	M1Hx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPIVIFHUUN3ME2xOE44PzNizszN	NGDnWItUSU6JRWK=
Capan-2	MnLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXwXolKSzVyPUG0Mlc5PiEQvF2=	MX\TRW5ITVJ?
SKG-IIIa	NH\CWG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTGPI1LUUN3ME2xOE45QDZ{IN88US=>	MVTTRW5ITVJ?
HEL	M3S2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3y2cWlEPTB;MUSuPFk6PyEQvF2=	NVzHS4l7W0GQR1XS
BEN	MnzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nacmlEPTB;MUSuPVc3PiEQvF2=	M3TrfXNCVkeHUh?=
MC116	NF7XXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTF3LkG1PVkh\|ryP	MWjTRW5ITVJ?
IGROV-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIixWnJKSzVyPUG1MlI{OTdizszN	NUSwVI41W0GQR1XS
NCI-H1648	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1ntNWlEPTB;MUWuOVMxPSEQvF2=	NHHIZ3NUSU6JRWK=
ABC-1	NXzVUppnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTF3LkiwN\|Mh\|ryP	MVvTRW5ITVJ?
EW-18	NF\MeGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLqOY5QUUN3ME2xOU46QTd7IN88US=>	NXSyelloW0GQR1XS
BC-3	NGLleFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTF4LkC1OlIh\|ryP	MVLTRW5ITVJ?
NCI-H1437	MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1:4O2lEPTB;MU[uNFY3PyEQvF2=	NEPCVJVUSU6JRWK=
SCC-15	M4LFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVGyNnJ5UUN3ME2xOk4zQDJ3IN88US=>	NVrveIxHW0GQR1XS
TT	NHj0eGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LibGlEPTB;MU[uOVg5QCEQvF2=	NWLrVYNOW0GQR1XS
KINGS-1	NUnMWHRUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTF4LkiyO\|Mh\|ryP	MkHpV2FPT0WU
C32	NEXkTVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWP6T2NjUUN3ME2xOk46PzF5IN88US=>	M{W5VHNCVkeHUh?=
SBC-5	M{\KeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXaTldKSzVyPUG3MlE1PzlizszN	M1zkZXNCVkeHUh?=
NB1	MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTF5LkOxPFgh\|ryP	M1z6WHNCVkeHUh?=
EB-3	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTF5LkW3OkDPxE1?	NVWwd\|AyW0GQR1XS
NCI-H748	Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PVe2lEPTB;MUeuO\|A{PSEQvF2=	MojMV2FPT0WU
IST-SL1	M{GwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIn5eoxKSzVyPUG3Mlc2OjZizszN	M{fZUnNCVkeHUh?=
WM-115	NXLMfXVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\ONmNbUUN3ME2xO{45ODh3IN88US=>	MXHTRW5ITVJ?
NCI-H226	NFfoTW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\2VlFqUUN3ME2xO{46PTR4IN88US=>	M1;6W3NCVkeHUh?=
CAL-33	NEC2TGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYCwTI1VUUN3ME2xPE4zPzhzIN88US=>	M4TwSnNCVkeHUh?=
SCC-4	M2TmdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnewTWM2OD1zOD6zNlI6KM7:TR?=	NYfYcnRLW0GQR1XS
RMG-I	MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYiw[W4yUUN3ME2xPE43QTR5IN88US=>	MYXTRW5ITVJ?
KOSC-2	NEjXW\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\VNnRKSzVyPUG4Mlc4PDZizszN	M1PrPHNCVkeHUh?=
A2058	M1vHcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYL0dnFVUUN3ME2xPE45OjV3IN88US=>	Mn7rV2FPT0WU
HCC70	NWDkO2R[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTETWM2OD1zOT6zPFk1KM7:TR?=	NYnDbYQ1W0GQR1XS
C2BBe1	Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHf5SYNKSzVyPUG5MlQyPDhizszN	MUXTRW5ITVJ?
NCI-H650	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PFOGlEPTB;MUmuOVg6QSEQvF2=	NYf6NGxJW0GQR1XS
CAL-72	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzETWM2OD1zOT62O\|M4KM7:TR?=	MlrmV2FPT0WU
L-363	NFTMcJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVT1Z\|hXUUN3ME2yNE4xOjF{IN88US=>	NYHBd\|hvW0GQR1XS
SNU-423	M1S1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTJyLkGwOFMh\|ryP	M3e3NXNCVkeHUh?=
PLC-PRF-5	NULING81T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4KwXWlEPTB;MkCuN\|kxPiEQvF2=	NH\BR4xUSU6JRWK=
SW1463	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHrV2Z[UUN3ME2yNE41PTJ3IN88US=>	NGfGTZJUSU6JRWK=
769-P	MnLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml64TWM2OD1{MD62O\|Y6KM7:TR?=	M4rMTHNCVkeHUh?=
DMS-79	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13KbGlEPTB;MkCuPFQ6KM7:TR?=	Mmq2V2FPT0WU
Saos-2	NGW5WXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXPWHdxUUN3ME2yNE46PTV4IN88US=>	MmPHV2FPT0WU
CHP-126	M1XZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PDbWlEPTB;MkGuOFQ3OiEQvF2=	MlXpV2FPT0WU
SW837	NYWxUJpuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXkR\|VKSzVyPUKxMlQ6OzlizszN	NWO2RmVvW0GQR1XS
SHP-77	NG\kdpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTJzLk[xNlIh\|ryP	NIqxeWlUSU6JRWK=
DB	NX23dY9jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPYSpVEUUN3ME2yNU43OTR{IN88US=>	NEPNbYdUSU6JRWK=
ES5	NX7JU2pHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\WcopKSzVyPUKxMlY5PjRizszN	NIjIZ\|dUSU6JRWK=
COR-L23	NGn0VWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nTVGlEPTB;MkGuPFA2OSEQvF2=	NH;zd5ZUSU6JRWK=
KU-19-19	NXrNeodXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\1bIlKSzVyPUKxMlg6QDJizszN	MoW5V2FPT0WU
T84	MoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXae\|FKSzVyPUKxMlk5OTlizszN	NID5XpdUSU6JRWK=
NCI-H630	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXSTWM2OD1{Mj61N\|Y{KM7:TR?=	M2jOR3NCVkeHUh?=
LU-165	MnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTJ{LkW1OEDPxE1?	NFTQNY5USU6JRWK=
COLO-792	Mn3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\4OIZrUUN3ME2yNk44OTFzIN88US=>	NFv2W3lUSU6JRWK=
CAL-62	M1u5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF:xd\|FKSzVyPUKyMlc2OTdizszN	NIP0U3hUSU6JRWK=
HCE-T	MoT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTJ{Lki2NFYh\|ryP	MlPzV2FPT0WU
BB65-RCC	MmKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHaTWM2OD1{Mz6wN\|Q1KM7:TR?=	MmPMV2FPT0WU
SiHa	M1XTPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWL4UYNyUUN3ME2yN{4{QTZ6IN88US=>	MonCV2FPT0WU
NCI-H2081	M3zQdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXrZeHpFUUN3ME2yOE4xPjRzIN88US=>	NXnaV\|JNW0GQR1XS
U251	M{LZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTJ2LkC2Olgh\|ryP	Mn;WV2FPT0WU
LoVo	M1vwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTJ2LkmyPFIh\|ryP	NYTaWY1ZW0GQR1XS
GCIY	NV7pTHBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoP4TWM2OD1{NT6yPFc4KM7:TR?=	M4DxRXNCVkeHUh?=
NUGC-3	Ml7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFftTWJKSzVyPUK1MlM{OTZizszN	NFP3cFNUSU6JRWK=
LNCaP-Clone-FGC	NGT0eI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLDTWM2OD1{NT6zOFk5KM7:TR?=	M{P2XXNCVkeHUh?=
PA-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLjclRmUUN3ME2yOU43QDN\|IN88US=>	NHnzUnBUSU6JRWK=
OE33	MlzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTJ3Lk[4OVMh\|ryP	M4PWV3NCVkeHUh?=
HT-29	NX;XcWM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFj4UYdKSzVyPUK1Mlc5PzlizszN	MojaV2FPT0WU
RCM-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Gx[mlEPTB;MkWuPVY2PiEQvF2=	M2PMTXNCVkeHUh?=
NCI-H1522	NVnMbG5GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTPTWM2OD1{NT65PVEyKM7:TR?=	NWe1S5IyW0GQR1XS
LB373-MEL-D	Mni1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTJ4LkG3NFgh\|ryP	M3zlR3NCVkeHUh?=
NCI-H1436	MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnqfWVKSzVyPUK2MlI4OzhizszN	NUnpN\|NIW0GQR1XS
COLO-824	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XqUmlEPTB;Mk[uOFAxOiEQvF2=	NUnzVok1W0GQR1XS
CP50-MEL-B	M2XTW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTlPYRzUUN3ME2yOk42Pjd3IN88US=>	M2nlcnNCVkeHUh?=
EGI-1	NEHVbWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTJ5LkK2PVgh\|ryP	NELXSWZUSU6JRWK=
LAN-6	MoLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHwTWM2OD1{Nz6zOVk5KM7:TR?=	NWXJRZNQW0GQR1XS
GAK	NIHx[mpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzCTWM2OD1{Nz60NlI2KM7:TR?=	MXTTRW5ITVJ?
MDA-MB-175-VII	M2nKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLZbodKSzVyPUK3MlUxPTNizszN	NYnOVmx6W0GQR1XS
JVM-2	NXnNZYJUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37kZ2lEPTB;MkeuOlYzOiEQvF2=	MlrrV2FPT0WU
UACC-257	NIfaNm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTJ5Lk[4O\|gh\|ryP	NFfVeYJUSU6JRWK=
SW1783	NVzQbYVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DwXGlEPTB;MkeuO\|c5OyEQvF2=	M3fJe3NCVkeHUh?=
HT-3	NIX5TZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\OZWlEPTB;MkiuNlE3PiEQvF2=	NHLlempUSU6JRWK=
RL	NH6wU4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fGTGlEPTB;MkiuOVkyOSEQvF2=	MW\TRW5ITVJ?
TK10	NH3lZ5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DE[mlEPTB;MkiuOlU{PSEQvF2=	Ml3UV2FPT0WU
HT55	NXXm[Y1lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWmzVoZCUUN3ME2yPU4xPTZ3IN88US=>	M3X1bnNCVkeHUh?=
BT-20	NF;sPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2G0VWlEPTB;MkmuNFU5PiEQvF2=	M4S4[HNCVkeHUh?=
TGBC24TKB	NWnmcpNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmP4TWM2OD1{OT6xPFMyKM7:TR?=	MXzTRW5ITVJ?
HSC-2	M1\XUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4r1NWlEPTB;MkmuN\|AxOSEQvF2=	NInifYpUSU6JRWK=
COLO-205	M3WydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTJ7LkO5OFQh\|ryP	MVLTRW5ITVJ?
GT3TKB	NGfBVG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTJ7Lk[4O\|ch\|ryP	NYDDcYZkW0GQR1XS
T47D	M{PV[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzMflZKSzVyPUK5Mlg2QDJizszN	MUDTRW5ITVJ?
OMC-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkG0TWM2OD1\|MD6xPVE6KM7:TR?=	MXjTRW5ITVJ?
PFSK-1	NV3EOVVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;YTWM2OD1\|MT6yOlU6KM7:TR?=	MUjTRW5ITVJ?
JEG-3	NEHIVJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTScJVoUUN3ME2zNU4{PTZzIN88US=>	M{TqfHNCVkeHUh?=
RD	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DCZmlEPTB;M{GuOVEyPSEQvF2=	NVnhN2V7W0GQR1XS
NCI-H64	NWHBVo9sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTN{LkSxO\|kh\|ryP	MXrTRW5ITVJ?
DMS-114	M2nxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1qzZ2lEPTB;M{KuOFE5OiEQvF2=	Mlu5V2FPT0WU
NCI-H661	NVHn[VdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{P6S2lEPTB;M{KuOlUxOSEQvF2=	M{D1ZXNCVkeHUh?=
CAL-148	NEPQbFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnUbJd1UUN3ME2zNk43PjZ3IN88US=>	NFK0N5dUSU6JRWK=
HuP-T3	M2C1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkXxTWM2OD1\|Mj65N\|M5KM7:TR?=	NGj3U5pUSU6JRWK=
ES4	NXzWV\|V3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjBOJhKSzVyPUOzMlE4ODVizszN	NYiyelJ2W0GQR1XS
Ca9-22	MmP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIroVFFKSzVyPUOzMlQ3ODFizszN	M17OOnNCVkeHUh?=
LP-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrqVmMxUUN3ME2zOE4xQSEQvF2=	NHHQWYlUSU6JRWK=
AU565	NYD4d3NXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrBZ\|ZKSzVyPUO0MlUxPjlizszN	MmC2V2FPT0WU
MDA-MB-453	NVXneldDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzt[ZRKSzVyPUO1MlE1OjZizszN	MXzTRW5ITVJ?
SNU-C1	NGrw[nVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTN3LkG3NUDPxE1?	NWX2TFViW0GQR1XS
SW13	NHzrUY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXj6Ond5UUN3ME2zOU41ODd4IN88US=>	M1rGZnNCVkeHUh?=
NCI-H2122	NX32R4JRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTN3LkW1PVgh\|ryP	NHLib\|VUSU6JRWK=
NCI-H1395	M4nDeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{ezWmlEPTB;M{WuOlY6OSEQvF2=	MoDEV2FPT0WU
J-RT3-T3-5	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTN4LkCyPVQh\|ryP	MWnTRW5ITVJ?
COR-L279	MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PzUGlEPTB;M{[uNVk5OSEQvF2=	Ml7iV2FPT0WU
ATN-1	NH\RSXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHpTWM2OD1\|Nj64OVE3KM7:TR?=	NWSyVnBRW0GQR1XS
HCC2998	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDlcZlKSzVyPUO2Mlg2PzFizszN	M{jyXHNCVkeHUh?=
UM-UC-3	MlyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrwVVFGUUN3ME2zOk45Pjd3IN88US=>	MmrpV2FPT0WU
DV-90	M3PCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTN4LkmwOlch\|ryP	NYr0cGpEW0GQR1XS
ES8	NVe3OoU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTN4LkmzNVgh\|ryP	NUjNPHo{W0GQR1XS
YAPC	M3\2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfEfXNIUUN3ME2zOk46PjV2IN88US=>	NFW2SW5USU6JRWK=
HCC1599	NWD1N\|ZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LG[2lEPTB;M{euNVYyQCEQvF2=	MmewV2FPT0WU
UMC-11	NUnjWHJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\D[GlEPTB;M{euNlUxOyEQvF2=	MmfUV2FPT0WU
THP-1	NVrVcVE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjzTWM2OD1\|Nz6yPFY5KM7:TR?=	NIDvfWJUSU6JRWK=
OCUB-M	NFnrOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHBWlJKSzVyPUO3MlI5QTFizszN	NGPUd4xUSU6JRWK=
NCI-H1693	NW\ud3l2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnkTWM2OD1\|Nz6zNlM{KM7:TR?=	M1XEbHNCVkeHUh?=
NCI-H345	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUP0OGx7UUN3ME2zO{4{PjJ2IN88US=>	NFvJT5dUSU6JRWK=
COLO-800	NIjKVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfGV4VKSzVyPUO3MlU3PyEQvF2=	NIK5cHdUSU6JRWK=
COLO-320-HSR	M3zt[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYO4bosxUUN3ME2zPE4{PDl{IN88US=>	M4nNRXNCVkeHUh?=
NCI-H596	NGXUUVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jJS2lEPTB;M{iuOFQ5QSEQvF2=	NVznO2RqW0GQR1XS
NCI-H187	NYrwVo14T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LNO2lEPTB;M{iuO\|M1PCEQvF2=	MXLTRW5ITVJ?
ECC4	MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTVPWNSUUN3ME2zPU4xQDF2IN88US=>	MWLTRW5ITVJ?
KP-4	NWnmfWdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTN7LkGyN\|Uh\|ryP	MXzTRW5ITVJ?
NCI-H2227	M2jJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmf0TWM2OD1\|OT6zPVQ6KM7:TR?=	MoWyV2FPT0WU
22RV1	NHnTc2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXTTWM2OD1\|OT64N\|k5KM7:TR?=	NWDUbmxwW0GQR1XS
SAS	NUKyPXZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXKTWM2OD12MD6wPVYh\|ryP	NEPBSmdUSU6JRWK=
PANC-10-05	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTRyLkG4Nlgh\|ryP	M3m3RnNCVkeHUh?=
MDA-MB-468	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIL0XmxKSzVyPUSwMlU{PDZizszN	MW\TRW5ITVJ?
RPMI-7951	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTRzLkKwO\|Uh\|ryP	NIrIR5hUSU6JRWK=
BB49-HNC	NYrZU2NST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37vWWlEPTB;NEGuNlE4QSEQvF2=	NE[xboxUSU6JRWK=
23132-87	M{fm[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PnO2lEPTB;NEGuNlc{OiEQvF2=	NXi3RpBMW0GQR1XS
HCC1569	NF;XbVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmm5TWM2OD12MT6yPFg2KM7:TR?=	MknXV2FPT0WU
CP66-MEL	MnLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jMSWlEPTB;NEKuNVg5PiEQvF2=	MV\TRW5ITVJ?
K-562	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHhZmc4UUN3ME20Nk4zQDV2IN88US=>	MlrIV2FPT0WU
OCI-AML2	MkD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTR{Lki5O\|Qh\|ryP	Ml\DV2FPT0WU
SW756	Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTR\|LkCzPFgh\|ryP	M4LJfnNCVkeHUh?=
M14	NX23Z2sxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWr4UHI3UUN3ME20N{4{OTh7IN88US=>	NXe2RWlXW0GQR1XS
NCI-H1623	NHTyRmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPMcolKSzVyPUSzMlQ3PCEQvF2=	NF3FPWZUSU6JRWK=
KNS-81-FD	NWj4O3JsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfub4RKSzVyPUSzMlc3OiEQvF2=	M4rsWXNCVkeHUh?=
TGBC1TKB	NWTG[nJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTR\|LkmwPVkh\|ryP	NYrqcGJDW0GQR1XS
RERF-LC-MS	Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTR\|LkmyPFEh\|ryP	NYm3T5RrW0GQR1XS
PC-3	NIXlOohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDMOnBKSzVyPUS0MlQ{PDdizszN	NYnVS21vW0GQR1XS
HuP-T4	NGW5[WlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojJTWM2OD12ND60OFc1KM7:TR?=	NHP5bHpUSU6JRWK=
NCI-H510A	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rhTGlEPTB;NESuO\|A5KM7:TR?=	NHHGOFRUSU6JRWK=
LB2518-MEL	NWTReIc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmP1TWM2OD12ND63PVM4KM7:TR?=	M1jn[HNCVkeHUh?=
TE-5	NH\lcmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrWd5p4UUN3ME20OU46PThzIN88US=>	M2r3UHNCVkeHUh?=
EW-24	NYezUphCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHH2U2lKSzVyPUS2MlE4OjNizszN	Ml3pV2FPT0WU
LB647-SCLC	M{DPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PxbWlEPTB;NE[uNlE2PSEQvF2=	MUfTRW5ITVJ?
NCI-H524	NH2yd5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTKTWM2OD12Nj63NVg2KM7:TR?=	M1P1THNCVkeHUh?=
EW-11	NI\v[nNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfD[4NKSzVyPUS2Mlk{PzNizszN	MmrJV2FPT0WU
KALS-1	MnzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHWU2tKSzVyPUS3MlIxPjZizszN	NG\GRnFUSU6JRWK=
BT-474	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHW4c2VKSzVyPUS3MlQzOTZizszN	NIToNZZUSU6JRWK=
SK-N-AS	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\3[WlEPTB;NEeuPFg5KM7:TR?=	M3;rZXNCVkeHUh?=
HCC2157	M36wdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoToTWM2OD12OD6wO\|Yh\|ryP	MVXTRW5ITVJ?
HCC1954	NFTQXZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfxVYJKSzVyPUS4MlE4ODRizszN	NHjRVJVUSU6JRWK=
FADU	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTR6LkOwN\|Eh\|ryP	MUXTRW5ITVJ?
S-117	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTYTWM2OD12OD6zPFE2KM7:TR?=	NV23XHlPW0GQR1XS
LS-1034	NFeyPFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHRTWM2OD12OD63NFY4KM7:TR?=	MkfvV2FPT0WU
CAMA-1	NULZZYVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnKTWM2OD12OT61OVQ{KM7:TR?=	MYjTRW5ITVJ?
LU-134-A	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvDZmRKSzVyPUS5MlgxQDVizszN	MmToV2FPT0WU
NCI-H1838	NXzqc48{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDZSIYyUUN3ME20PU45ODh5IN88US=>	NVnBPFY3W0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pSrc / Src / pPlcg / Plcg / pStat5 / Stat5 ; PubMed: 22781593 Leukemia In (B) inhibition of Src, Plcg and Stat5 was seen in MLNAF cell lines treated with Ponatinib; ZNF112 expresses ZMYM2–FGFR1, CEP2A and CEP5A cells express CEP110–FGFR1 and BBC2 expresses BCR–FGFR1. pFGFR1(pY20) / FGFR1; PubMed: 22781593 Leukemia Western blot analysis, using various antibodies specific for downstream targets of FGFR1, demonstrates that Ponatinib inhibits the activation of Plcg and Src as a result of inhibiting the FGFR1 fusion kinase in human KG1 cells. cleaved caspase-3 / cleaved caspase-7 / BAX / Bcl-2; PubMed: 30959969 Molecules Western blot analysis of cleaved caspase-3, cleaved caspase-7, Bax, Bcl-2, and β-Tubulin (control) in treated cells. p-Rb(S807/811) / Rb / CDK4 / CDK6 / Cyclin D1 / CDK2 / Cyclin E1; PubMed: 30959969 Molecules Western blot analysis of Rb/p-Rb, CDK4, CDK6, Cyclin D1, CDK2, Cyclin E1, and β-Tubulin (control) in the SK-Hep-1 and SNU-423 cells treated with ponatinib. RAD51; PubMed: 30959969 Molecules The effect of ponatinib on the concentration of Rad51 in SK-Hep-1 and SNU-423 cells. p-MEK / MEK / p-ERK / ERK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Mek and Erk. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. c-Jun / p-JNK(T183/Y185) / JNK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of JNK and c-Jun. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-p38 MAPK / p38 MAPK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of p38. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-JAK2 / JAK2 / p-STAT3 / STAT3; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Jak2, and Stat3. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. PI3K p85 / p-PI3K / p-PDK1 / PDK1 / p-mTOR / mTOR; PubMed: 30959969 Molecules Effects of ponatinib on the protein concentration and phosphorylation of PI 3-kinase, PDK1, Akt, and mTOR in HCC cells. p-PDGFRα / PDGFRα; PubMed: 24472312 Mol Cancer Ponatinib inhibited phosphorylation of PDGFRα in a concentration-dependent manner. EOL-1 and BaF3-WT or -T674I FIP1L1-PDGFRα cells were exposed to escalating concentrations of ponatinib for 24 h. PARP / Caspase-3 / Active Caspase-3; PubMed: 24472312 Mol Cancer The concentration- (for 24 h) and time-dependent (1 nM for EOL-1, 300 nM for BaF3-WT and -T674I FIP1L1-PDGFRα cells) cleavage of PARP and caspase-3 triggered by ponatinib was analyzed by immunoblotting. AIF / Cyto C ; PubMed: 24472312 Mol Cancer Ponatinib elicited release of AIF and cytochrome c into the cytosol. Cells were treated with 1 nM ponatinib for the indicated durations and the cytosolic fraction was extracted with digitonin buffer. Levels of AIF and Cytochrome c (Cyto c) were detected by immunoblotting. Mcl-1 / Survivin / Bcl-Xl / XIAP / Bax / Bcl-2 / Bim; PubMed: 24472312 Mol Cancer Immunoblotting of apoptosis-related proteins in CEL cells after treatment for 24 h. β-catenin ; PubMed: 24472312 Mol Cancer Ponatinib concentration-dependently lowered β-catenin. EOL-1 cells were incubated with ponatinib for 24 h, and cytoplasmic and nuclear extracts were determined by immunoblotting. β-catenin; PubMed: 24472312 Mol Cancer Analysis of β-catenin localization. EOL-1 cells were pretreated with 1 nM ponatinib for 24 h, immunofluorescence analysis was performed with anti-β-catenin. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). ABL; PubMed: 19878872 Cancer Cell In vitro [γ-32P]-ATP autophosphorylation of full-length (A) ABL or (B) ABLT315I kinase treated with AP24534, imatinib, nilotinib, or dasatinib. After incubation of tyrosine-dephosphorylated enzyme with the indicated inhibitor in the presence of [γ-32P]-ATP and separation by SDS-PAGE, signal intensity was measured by autoradiography.	22781593 30959969 24472312 19878872
Growth inhibition assay	Cell viability; PubMed: 30174789 Oncotarget (A) Effect of Ponatinib on basal viability of HUVECs. The cells were treated with Ponatinib at indicated concentrations or 0.1% DMSO (vehicle control) for 24 h.	30174789

In vivo

In a mouse xenograft model of Ba/F3 cells expressing native Bcr-Abl, AP24534 (2.5 mg/kg and 5 mg/kg) prolongs mice median survival. In the xenograft model of Ba/F3 Bcr-Abl^T315I, AP24534 (10 mg/kg–50 mg/kg) significantly suppresses tumor growth. AP24534 (30 mg/kg) decreases the phosphorylated Bcr-Abl and phosphorylated CrkL levels in the tumors. ^[2]

Protocol

Kinase Assay:^[1]	+ Expand Peptide substrate phosphorylation assays with GST-Abl kinase domains: The effect of AP24534 (0-320 nM) on GST-Abl kinase activity is assessed by using a synthetic peptide substrate (Abltide: EAIYAAPFAKKK). Assays are carried out at 30 °C for 15 min in 25 μL reaction mixture: 8 mM MOPS (pH 7), 0.2 mM EDTA, 50 μM Abltide, 30 mM MgCl₂, 10 mM β-glycerol phosphate, 1 mM EGTA, 0.002% Brij-35, 0.4 mM DTT, 0.2 mg/mL BSA, 0.4 mM sodium orthovanadate, 10 nM WT or mutant GST-Abl kinase, and 100 µM ATP/γ-³²[P]ATP (5000 cpm/pmol). Reactions are terminated by transferring a portion of the reaction mixture onto a p81 phosphocellulose filter and immersing in 0.75% phosphoric acid. Filters are washed 3 times in 0.75% phosphoric acid, rinsed in acetone, and air dried; phosphate incorporation is determined by scintillation counting. All results are corrected for background binding to the filters, as determined by omitting peptide substrate from the kinase reaction. Time course experiments to establish the linear range of enzymatic activity precedes kinase assays.
Cell Research:^[2]	+ Expand Cell lines: Ba/F3 cells expressing Bcr-Abl or a range of single mutations in the kinase domain of Bcr-Abl Concentrations: 0-625 nM Incubation Time: 72 hours Method: Ba/F3 cell lines are distributed in 96-well plates (4 × 10³ cells/well) and incubated with AP24534 for 72 hours. Proliferation is measured using a methanethiosulfonate (MTS)-based viability assay (CellTiter96 Aqueous One Solution). All values are normalized to the control wells with no drug. IC50 values are reported as the mean of three independent experiments performed in quadruplicat (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: Mouse xenograft models of Ba/F3 cells expressing Bcr-Abl or Bcr-Abl^T315I Formulation: Dissolved in 25 mM citrate buffer, pH 2.75 Dosages: 2.5 mg/kg and 5 mg/kg for Ba/F3 Bcr-Abl; 2.5 mg/kg–50 mg/kg for Ba/F3 Bcr-Abl^T315I Administration: Oral gavage once daily (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	30 mg/mL (56.33 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% CMC Na For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Ponatinib (AP24534) SDF

Molecular Weight	532.56
Formula	C₂₉H₂₇F₃N₆O
CAS No.	943319-70-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03838692	Not yet recruiting	Medullary Thyroid Cancer	Antonio Fojo\|Millennium Pharmaceuticals Inc.\|Columbia University	April 2019	Phase 2
NCT03838692	Not yet recruiting	Medullary Thyroid Cancer	Antonio Fojo\|Millennium Pharmaceuticals Inc.\|Columbia University	April 2019	Phase 2
NCT03878524	Not yet recruiting	Breast Cancer\|Prostate Cancer\|Pancreatic Cancer\|Acute Myelogenous Leukemia	OHSU Knight Cancer Institute\|Oregon Health and Science University\|Prospect Creek Foundation	March 14 2019	Phase 1
NCT03878524	Not yet recruiting	Breast Cancer\|Prostate Cancer\|Pancreatic Cancer\|Acute Myelogenous Leukemia	OHSU Knight Cancer Institute\|Oregon Health and Science University\|Prospect Creek Foundation	March 14 2019	Phase 1
NCT03807479	Recruiting	Leukemia Myeloid Chronic-Phase	GWT-TUD GmbH\|Incyte Biosciences International Sàrl	December 11 2018	Phase 2
NCT03807479	Recruiting	Leukemia Myeloid Chronic-Phase	GWT-TUD GmbH\|Incyte Biosciences International Sàrl	December 11 2018	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is the pre-solubilized inhibitor suitable for in vivo whole animal studies? Whether the solvent contains any non-DMSO stabilizer?
Answer:
Our 10mM Ponatinib in DMSO solution is in pure DMSO and there is not other stabilizer added. You can use it for animal study. The vehicle we suggest for Ponatinib is: 30% PEG400/0.5% Tween80/5% Propylene glycol. It is a milky suspension used for oral gavage.

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

Selective Bcr-Abl Inhibitor

Nilotinib (AMN-107) : Bcr-Abl-selective, IC50<30 nM.
Most Potent Bcr-Abl Inhibitor

GZD824 : Bcr-Abl(WT), IC50=0.34 nM; Bcr-Abl(T315I), IC50=0.68 nM.
FDA-approved Bcr-Abl Inhibitor

Dasatinib : Approved by FDA for CML and Ph+ ALL.
Newest Bcr-Abl Inhibitor

GZD824 : Orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

Related Bcr-Abl Products4

PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.
Defactinib (VS-6063, PF-04554878) ^New

Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.
SU6656 ^New

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
Imatinib Mesylate (STI571)

Imatinib Mesylate (STI571) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.
Nilotinib (AMN-107)

Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells.

Features:A selective inhibitor of native and mutant Bcr-Abl.
Bafetinib (INNO-406)

Bafetinib (INNO-406) is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM/19 nM in cell-free assays, does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and c-Kit. Phase 2.

Features:Dual Bcr-Abl/Lyn inhibitor.
Degrasyn (WP1130)

Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT).

Features:WP1130 has an advantage over imatinib mesylate in that its activity is not inhibited by a variety of Abl kinase mutations, including T315I.
Rebastinib (DCC-2036)

Rebastinib (DCC-2036) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1.

Features:A conformational control inhibitor of Abl1 and T315I Abl1.
GZD824 Dimesylate(HQP1351)

GZD824 Dimesylate is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.
GNF-2

GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl, shows no activity to Flt3-ITD, Tel-PDGFR, TPR-MET and Tel-JAK1 transformed tumor cells.

Choose Your Country or Region

By Signaling Pathways

By product type

Ponatinib (AP24534)

Cited by 36 Publications

Purity & Quality Control

Choose Selective Bcr-Abl Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Ponatinib (AP24534) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

Related Bcr-Abl Products4

Choose Your Country or Region

By Signaling Pathways

By product type

Ponatinib (AP24534)

Cited by 36 Publications

Purity & Quality Control

Choose Selective Bcr-Abl Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Ponatinib (AP24534) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

Related Bcr-Abl Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)